CureVac N.V. Announces Extraordinary General Meeting for Merger with BioNTech SE

CureVac N.V. has convened an extraordinary general meeting of shareholders to be held on November 25, 2025, to discuss and vote on the proposed merger with BioNTech SE. The meeting will address several key items, including the legal merger of CureVac with CureVac Merger B.V., the subsequent sale and transfer of shares to BioNTech, and the cancellation of class A shares in CureVac Merger B.V. The merger is part of a broader post-offer reorganization following BioNTech's tender offer for CureVac shares. The meeting will also cover the conditional release of liability for managing and supervisory directors, and the appointment of new directors. The merger and related transactions are subject to shareholder approval and other conditions outlined in the Purchase Agreement between CureVac and BioNTech.